Madrid will host the first One Health Congress in Spain
Madrid, February 15, 2024. – The One Health Platform organizes the First National Congress “Building Modern Public Health Together” on April 11 and 12. Two days where attendees will be able to expand the One Health vision to improve understanding of what this approach means and thereby contribute to the different areas of competence of […]
CUATRO Stories about antibiotic resistance with the participation of Domingo Gargallo
See the full stories here.
Interview with our CEO & representative of the BEAM Alliance in Spain, Domingo Gargallo for the newspaper El Global
Domingo Gargallo has been interview by the newspaper El Global to discuss research for new antibiotics in Spain, compared to other European countries. As Domingo Gargallo explains, «The great handicap at the moment is that pharmaceutical companies are not interested and, therefore, do not act as a driving force in the entire chain of generation […]
ABAC Therapeutics and the University of Santiago de Compostela form a joint unit of screening for the discovery of new antimicrobial agents
September 28, 2023.- Infections caused by resistant bacteria to antibiotic are, currently, one of the biggest global health problems, in terms of mortality, social and economic impact1. Multi-resistant bacteria cause 1.27 million deaths a year2, and the World Health Organization estimates that, by 2050, they will be the main cause of mortality in the world, […]
Domingo Gargallo-Viola has been elected to be part of the Executive Board of the BEAM Alliance!
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical […]
The One Health Platform has been awarded in the 2nd edition of the “El Escarabajo Verde” Awards granted by RTVE (Spanish Public Radio and Television) with the aim of highlighting the work for the conservation of the environment in different areas of society.
During the same week of World Environment Day, RTVE will celebrate the delivery of the 2nd edition of the “Escarabajo Verde” Awards, whose objective is to highlight the work for the conservation of the environment in different areas of society. The One Health Platform has received the award in the category ‘public or private organization for its […]
ABAC is hiring!
Cell permeability assessment and integration of innovative small molecules for antibacterial R&D You will contribute to the development and validation of in vitro tests and algorithms to determine antimicrobial activity and toxicity of novel antimicrobial molecules in the BREAKthrough project. Your mission will be the development and validation of microbiology and in vitro tests, computer […]
ABAC Therapeutics joins the One Health platform oriented towards a comprehensive approach to Health
The One Health Platform is a state-wide network that unites the efforts of more than 100 national collegiate organizations, associations, foundations and companies belonging to different fields and sectors, giving it the interdisciplinary and intersectoral nature that the “One Health” concept requires. This concept refers to the health of people, animals and ecosystems. In this […]
ABAC THERAPEUTICS participates in the European BREAKthrough project to overcome antimicrobial resistance
An alarming number of infections have become hard or impossible to treat due to the high percentage of bacteria resistant to existing antibiotics. Antimicrobial resistance is considered one of today’s greatest health threats facing humanity. With innovation in the development of new antibiotics lacking, other solutions are urgently needed. A new EU-funded research and training programme, […]
Increasingly resistant bacteria and no innovative drugs for six decades
Antimicrobial resistance is one of the major global public health problems. Almost all antibiotics introduced to the market are improved versions of broad-spectrum products approved before 1962. The WHO warns that research in this field is «stagnant.» Gargallo-Viola, CEO and CSO of ABAC Therapeutics, who is participating in this article, is president of the Association […]
